Ampersand Capital Partners

Ampersand Capital Partners is a private equity firm based in Massachusetts, established in 1988. The firm specializes in making investments in the lower mid-market sector, focusing primarily on healthcare and industrial companies. With a commitment to supporting growth in these core areas, Ampersand seeks to partner with businesses that demonstrate strong potential for development and innovation. The firm's expertise in the healthcare sector positions it well to identify and nurture companies that can deliver impactful solutions and services.

Scott Anderson

Associate

David Q. Anderson

General Partner

Stuart A. Auerbach

Advisory Partner

Jared J. Bartok

Advisory Partner

Richard A. Charpie

Founder

Melanie Fan

Principal

Herbert Hooper

Managing Partner

Thomas de Jager

Vice President, Business Development

Eric B. Lev

General Partner

Greg W. Magoon

Vice President

Jenna N. Mark

Associate

Alex Marotto

Senior Associate

Caroline L. Marple

Director of Marketing

Arya Mehrabanzad

Vice President

Dana L. Niles

Partner and COO

David J. Parker

General Partner

David B. Patteson

Partner

Marina Pellón-Consunji

Partner

Mario J. Reto

Senior Associate

Geoffrey P. Teillon

Partner

Trevor Wahlbrink

Partner

96 past transactions

ALPCO Diagnostics

Acquisition in 2020
American Laboratory Products offers a wide range of testing solutions, providing scientists and healthcare professionals with vital insights for advancing research and quality of care.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Genome Diagnostics B.V.

Private Placement in 2019
Genome Diagnostics B.V., trading as GenDx, develops and markets a line of in vitro diagnostic (IVD) tests, analysis software, and education courses focusing on sequencing-based typing (SBT) for transplantation. The company’s products include SBTexcellerator, optimised reagents for Sanger SBT; SBTexcellerator Supplement; SBTengine, which enables analysis of HLA loci using Sanger sequencing technology for complete high-resolution typing; SBTessenz, high-throughput Sanger SBT HLA typing reagents; NGSgo Full Workflow; NGSengine, a sequencing HLA analysis software; Chimerism Monitoring; and AlleleSEQR. It also offers laboratory services. The company partners with Linkage Biosciences, Kyratec, and QIAGEN. It distributes its products directly as well as by their HLA-specialised distributors. Genome Diagnostics B.V. was founded in 2005 and is based in Utrecht, the Netherlands.

Sterling Medical Devices

Private Equity Round in 2022
Sterling Medical Devices, a fully staffed U.S. based medical device engineering firm.

FirstRain

Venture Round in 2010
FirstRain, Inc. develops a business analytics platform that assists Fortune 1000 companies in building their strategies, creating lead generation campaigns, discovering and developing new sales opportunities, and identifying business risks. The company was founded in 2000 and is headquartered in San Mateo, California. As of July 31, 2017, FirstRain, Inc. operates as a subsidiary of Ignite Technologies, Inc.

Sanova Dermatology

Seed Round in 2013
Sanova Dermatology, PLLC offers cosmetic dermatology services. The company offers treatments for wrinkle reduction, acne, moles, and skin cancer. The company is headquartered in Austin, Texas.

Vibalogics

Merger/Acquisition in 2019
Vibalogics is a contract development and manufacturing organization focused on complex live biological products. Vibalogics offers process development, manufacturing and fill & finish of products for biopharmaceutical companies involved in the development of oncolytic viral therapies, gene therapies, and vaccines.

Arranta Bio

Series B in 2021
Arranta Bio was formed in May 2019 with the vision to be the best-in-class microbiome CDMO, developing and manufacturing live biotherapeutic products (LBPs) for pioneers targeting diseases linked to the microbiome, using bacterial fermentation, isolation, drying and encapsulation. In October 2019, we completed an $82,000,000 funding round with sole institutional investor, Ampersand Capital, company founders and colleagues, and a strategic investment from Thermo Fisher Scientific.

BioEcho Life Sciences

Private Equity Round in 2022
BioEcho Life Sciences develop and produce next-generation technologies and products to enable molecular biology and diagnostics laboratory workflows of higher convenience, higher robustness, and higher sustainability.

FirstRain

Series B in 2003
FirstRain, Inc. develops a business analytics platform that assists Fortune 1000 companies in building their strategies, creating lead generation campaigns, discovering and developing new sales opportunities, and identifying business risks. The company was founded in 2000 and is headquartered in San Mateo, California. As of July 31, 2017, FirstRain, Inc. operates as a subsidiary of Ignite Technologies, Inc.

Gyros Protein Technologies

Acquisition in 2015
Protein Technologies supply quality peptide synthesizers and reagents to universities, biotechnology companies, pharmaceutical companies and peptide houses.

New England Peptide

Private Equity Round in 2019
New England Peptide prides itself on providing top-notch peptides and excellent customer service. We strive to constantly better ourselves and, in the process, the industry.

Canopy Biosciences

Private Placement in 2019
Canopy Biosciences is biotechnological company that provides products and services for gene editing and personalized medicine. The gene editing technology is called TUNR and targets translation elongation by inserting polyA tracks into targeted coding regions of the genome. This change then decreases the levels of mRNA transcribed from the gene and therefore suppresses protein expression. It was initially developed by Professor Sergej Djuranovic at Washington University School of Medicine and Professor Rachel Green from Johns Hopkins University. Canopy Biosciences was formed in 2016 and is headquartered in Saint Louis, Missouri.

NutraMed

Debt Financing in 2014
Nutramed, Inc. develops, manufactures, and markets tablet, capsule, and powder nutritional supplement products for customers in the United States and internationally. It offers a range of manufacturing services, including blending, granulation, tableting, timed release formulation, bilayer tablets, various types of tablet coatings, two-piece hard-shell encapsulation, stick-packs, multi-packs, blister cards, pack out, powder packaging, and tablet and capsule packaging. The company also offers enteric coating on tablets, capsules, and soft gels. The company was founded in 1998 and is headquartered in Chino, California
Blackstone Technology Group provides software and services that create high throughput computing environments. Blackstone helps customers speed time-to-market by designing and optimizing infrastructures for high user productivity, low administrative burden, and low ownership cost. Blackstone accomplishes these goals with Consultants who have expertise in the applications and process methodologies, as well as in the design and optimization of large-scale, high-throughput computing environments; and Software products that simplify usage and administration of the environment, as well as maximize computing throughput and architecture scalability.

LightPointe

Venture Round in 2004
LightPointe Communications, Inc. (a.k.a. LightPointe Wireless) is privately held. The company was launched in 1998 and is headquartered in San Diego, CA, with regional offices/presence in Europe (Germany & France) and Asia (Thailand). LightPointe also provides solutions via its AirePointe Security & Government Solutions Division (www.AirePointe.com). LightPointe is the number one manufacturer in the world of point-to-point Gigabit Ethernet Free Space Optics and Hybrid Optical-Radio Bridges, and manufactures a complete line of 4G/LTE backhaul radios (60 GHz & 70/80 GHz e-band) for telecom carriers and enterprises such as businesses, schools, the military & government agencies. With over $80 million in product development and over eight key patents, LightPointe has deployed thousands of Gigabit Ethernet bridges and digital video/security backhaul solutions worldwide.

Vernal Biosciences

Venture Round in 2022
Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.

CRI Lifetree

Seed Round in 2007
CRI Lifetree operates as a specialized research organization. The Company focuses on the conduct and design of early stage endocrinology and infectious disease research products and services. CRI Lifetree provides clinical research throughout the United States.

Arranta Bio

Private Placement in 2019
Arranta Bio was formed in May 2019 with the vision to be the best-in-class microbiome CDMO, developing and manufacturing live biotherapeutic products (LBPs) for pioneers targeting diseases linked to the microbiome, using bacterial fermentation, isolation, drying and encapsulation. In October 2019, we completed an $82,000,000 funding round with sole institutional investor, Ampersand Capital, company founders and colleagues, and a strategic investment from Thermo Fisher Scientific.

Agilux Laboratories

Seed Round in 2008
Agilux Laboratories is a contract research organization. The company offers a range of services supporting discovery, pre-clinical, and clinical services. It provides a range of drug metabolism and pharmacokinetic services for biotech and pharmaceutical industries. The company’s services include discovery bioanalytical, GLP bioanalytical, in vivo, in vitro, and Immunoassays services. It focuses on bioanalytical and PK/PD testing services for the biotech and pharmaceutical industries. Agilux Laboratories was founded by Peter Glick in 2007 and is headquartered in Worcester, Massachusetts.

Medifacts International

Series A in 2005
As of February 5, 2010, Medifacts International, Inc. was acquired by CoreLab Partners. Medifacts International, Inc. provides cardiovascular safety monitoring services to the pharmaceutical and biotech industry. The company offers electrocardiogram (ECG) services, digital Holter services, ambulatory blood pressure monitoring, automated blood pressure, telemedicine, and assessment of arterial stiffness in clinical trials, as well as glucose monitoring and pulmonary services. It also provides consulting and medical writing services, including expert program and protocol design, protocol development, expert interim reports, statistical analysis plans and reports, ECG analysis, regulatory guidance and support, expert summary reports for inclusion in the clinical study reports, and statistical analysis planning and biostatistics, as well as digital data collection, transmission, and analysis. The company was founded in 1985 and is headquartered in Rockville, Maryland with additional offices in Langenfeld, Germany; and Shanghai, China.

Blue Sky Biotech

Private Equity Round in 2011
Blue Sky Biotech, Inc. is a Contract Research Organization (CRO) in the pharmaceutical R&D market. As a trusted partner to nine of Fortune’s Top 10 Pharmaceutical Companies, Blue Sky has a proven track record with industry leaders. Blue Sky aims to alleviate the onerous and labor-intensive tasks that take scientists away from key experimentation, novel theory exploration and other optimal uses of their time. Blue Sky is synonymous with productivity in the early discovery biology processes known as genetic cloning, recombinant protein expression and laboratory-scale fermentation (scale-up bioprocessing). We are motivated by our ability to impact the overall efficiency of the drug discovery process, thus contributing to a longer, healthier lifespan for human beings.

Néomed-Labs Inc

Merger/Acquisition in 2018
Néomed-Labs Inc provides clinical immunology laboratory services. Its services include immunomonitoring testing; assay development, qualification, validation, and testing; protein optimization services; project consultancy and management; and sample management services. Néomed-Labs Inc also provides contract research services. It caters to pharmaceutical and biotechnology industries. Néomed-Labs Inc was founded in 2016 and is based in Laval, Canada.

Magellan Diagnostics

Private Equity Round in 2006
Magellan Diagnostics, Inc., a medical device company, develops and manufactures point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing. Its products include LeadCare II, a blood lead testing system; LeadCare Ultra, which provides blood lead results for laboratories; and LeadCare Plus, a solution for laboratories with smaller volumes for performing lead testing in house. The company also provides various analytical services, such as lead and heavy metal exposure, monitoring exposure in employees, and testing. It offers solutions for clinicians, public health providers, managed care organizations, and families and communities. Magellan Diagnostics, Inc. was formerly known as Magellan Biosciences, Inc. The company was founded in 2004 and is headquartered in North Billerica, Massachusetts. Magellan Diagnostics, Inc. operates as a subsidiary of Magellan Biosciences, Inc.

Proficiency

Series D in 2004
Proficiency, Inc. provides product knowledge integration and CAD interoperability solutions that enable manufacturers and suppliers to share product knowledge from various engineering and manufacturing environments. Its solutions include product knowledge migration, which delivers a process of technology and methodology that meets migration needs; and supplier delivery solutions to original equipment manufacturers or higher tier suppliers. The company’s products also include Collaboration Gateway V7.0, which enables the transfer of the product knowledge between CAD systems that include geometry, features, sketches, manufacturing info, metadata, assembly information, and drawings in the conversion process; and Completion Wizard, which provides an interactive method of completing the process. In addition, it offers CAD translation services, such as geometry-only, product knowledge, and associative drawing translations; consulting services, such as migration strategy, supplier delivery strategy, and process integration consulting; and implementation services, such as training, customer support, and customer specific developments. The company serves various companies in the automotive, aerospace and defense, and heavy machinery industries. Proficiency, Inc. was founded in 1998 and is based in Marlborough, Massachusetts. As of July 1, 2009, Proficiency, Inc. operates as a subsidiary of ITI TranscenData.

Gyros Protein Technologies

Merger/Acquisition in 2015
As per the transaction announced on March 16, 2016, Protein Technologies, Inc. operates as a subsidiary of Gyros AB.
American Laboratory Products Company, Ltd., doing business as ALPCO Diagnostics, offers testing solutions for scientists and healthcare professionals. Its solution includes STELLUX, chemiluminescence ELISA platform for detecting key biomarkers in life science research. The company focuses on providing assays and life science research tools for academic, pre-clinical, and clinical use. It offers applications for HPLC, LC-MS/MS, purified antibodies, recombinant proteins, flow cytometry reagents, Immunoassays, and chemiluminescent based detection systems; and plasma cell dyscrasias screening tubes. The company provides its products in various therapeutic areas, such as allergy and infectious disease, bone metabolism, CVD and oxidative stress, diabetes and obesity, endocrinology, gastroenterology, immunology, neurobiology, toxicology, antibodies and antigens, and accessories. American Laboratory Products Company, Ltd. was founded in 1990 and is based in Salem, New Hampshire.

ProGene Biomedical

Venture Round in 2004
ProGene Biomedical is a clinical reference laboratory specializing in clinical immunology and allergy testing.

LakePharma

Private Equity Round in 2017
LakePharma is a contract research organization (CRO) specializing in antibody and protein engineering, cell line development, and protein production. The company's range of services covering areas such as antibody engineering, antibody discovery, molecular engineering, protein chemistry, bioexpression, biofunction, bioprocessing and bioanalytics focus on integrated platforms to support projects throughout the drug discovery process and offers dedicated client services and sophisticated software to provide real-time access to project data via a secure cloud-based portal enabling clients to accelerate product development from lead discovery to Phase 1 clinical trials. Located in the heart of the San Francisco Bay Area, LakePharma has developed numerous in-house technology platforms to provide cost-effective and high quality services to its customers. The production processes are SOP-based and high-throughput, and have been streamlined to be exceptionally efficient on both a small and large scale. Each project is actively managed by a dedicated study director to ensure timely completion with superior results and transparent communication. Clients have real-time access to their project data and can view and receive status updates through LakePharma’s secure cloud-based Datasystems. LakePharma follows the principles of Good Laboratory Practices (GLP) to ensure the quality, reliability and integrity of study data. Upon request, services can also be performed in full compliance with FDA documentation requirements for submissions for nonclinical laboratory studies. All services are provided solely on a fee-for-service basis and are royalty-free.

CutisPharma

Private Equity Round in 2015
Azurity Pharmaceuticals is a developer of drug products and technologies to address the needs of patients. Its drug products such as antimicrobial, mouthwashes, and testosterone enable pharmacists to prepare drugs for those populations who are in need of a better alternative to traditionally-compounded medications.

GeneWerk

Acquisition in 2020
GeneWerk GmbH was founded in July 2014 by Prof. Dr. Christof von Kalle, Dr. Manfred Schmidt and Dr. Annette Deichmann with participation of the German Cancer Research Center (DKFZ) Heidelberg. their team has long lasting experience in the area of integration site analysis, high throughput sequencing, whole genome sequencing and bioinformatics. It is very innovative in developing new analysis methods – perhaps also for your project?

Endeca

Series C in 2004
Endeca provides enterprise search for large companies including Borders, Boeing, the Census Bureau, the EPA, Ford, Hallmark, IBM, and Toshiba. The company specializes in guided search, auto-categorizing results based on the keywords someone enters. Endeca charges from $100,000 to more than $10 million per installation. Endeca competes with FAST Search & Transfer, which was [acquired](http://www.techcrunch.com/2008/01/08/microsoft-has-announced-a-takeover-bid-for-fast-search-transfer-priced-at-12-billion/) by Microsoft for 1.2 Billion in January 2008.

Nexcelom Bioscience

Private Equity Round in 2018
Nexcelom Bioscience LLC, a biotechnology company, develops and markets image cytometry products for cell analysis in life science and biomedical research. It offers Cellometer, helps to count and analyze cell lines and primary cells, through bright field and fluorescence imaging modes; and Celigo, which provides high image quality, high throughput image cytometry system for adherent and suspension cells in microwell plates. Additionally, the company also offers fluorescent reagents and kits for cell counting and cell-based assays. The company provides its products for life science industry. The company was incorporated in 2003 and is based in Lawrence, Massachusetts.

NEOMED-LABS

Acquisition in 2018
NEOMED-LABS is a provider of clinical immunology laboratory services for biologics drug development. NEOMED-LABS is an independent, pure player in the immunology field whose team of experts and state of the art BSL2 labs were instrumental in the development, qualification, and validation of more than 30 assays supporting the FDA filing of 10 marketed vaccines whose cumulative sales is around $3bn. Our unrivaled expertise in immunotools engineering and stability testing, as well as our capacity of 200k results per year on our immunochemistry, virology, and bacteriology automated platforms are devoted to personalized services and fast track method validation.

FirstRain

Venture Round in 2008
FirstRain, Inc. develops a business analytics platform that assists Fortune 1000 companies in building their strategies, creating lead generation campaigns, discovering and developing new sales opportunities, and identifying business risks. The company was founded in 2000 and is headquartered in San Mateo, California. As of July 31, 2017, FirstRain, Inc. operates as a subsidiary of Ignite Technologies, Inc.

Arranta Bio

Venture Round in 2019
Arranta Bio was formed in May 2019 with the vision to be the best-in-class microbiome CDMO, developing and manufacturing live biotherapeutic products (LBPs) for pioneers targeting diseases linked to the microbiome, using bacterial fermentation, isolation, drying and encapsulation. In October 2019, we completed an $82,000,000 funding round with sole institutional investor, Ampersand Capital, company founders and colleagues, and a strategic investment from Thermo Fisher Scientific.

Ensemble Communications

Venture Round in 2002
Ensemble Communications develops wireless infrastructure equipment for high-speed local broadband access applications.

Assay Designs

Series A in 2005
Assay Designs, founded in 1992, provides quality, rapid, and easy-to-use products for the worldwide biomedical, pharmaceutical and scientific research communities to "Simplify Your Science®". Thier rapidly expanding product line includes kits and materials for the detection and quantification of molecules that are important in cell regulation, signal transduction, inflammation, oxidative processes and apoptosis. Assay Designs develops, produces and markets CORRELATE™ and TITERZYME® immunoassay kits, detection kits, FLASHLIGHT® and BIOLIGHT™ luminescent compounds, antibodies and miscellaneous compounds. Providing unsurpassed precision and reproducibility, Assay Designs offers a broad range of eicosanoid kits and human and mouse cytokine kits and the world's only non-radioactive COX activity kit. In addition, a wide selection of related antigen and antibody products are available to meet your specific research needs. Assay Designs also offers contract manufacturing and custom design products for specialized research needs.
Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company’s discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and third-generation programs in HIV maturation inhibition. The company was founded in 1999 and is headquartered in Watertown, Massachusetts.

RadPharm

Acquisition in 2005
RadPharm provides radiopharmaceutical products to medical practices in Australia. Its product portfolio includes sterile vials, cold kits, contract manufacturing, and more.

ProtaGene

Private Equity Round in 2023
ProtaGene is an analytic service provider across the biopharmaceutical, cell, and gene therapy development spaces. They provide complete protein and gene analytic capabilities and packages for biologic therapeutics as well as cell and gene therapy platforms. They offer product testing and analytical packages for product lifecycle management.

Detector Technology

Private Equity Round in 2018
Detector Technology, Inc. is a world-class leading manufacturer of products and systems for OEM and equipment manufacturers. DeTech specializes in Channel Electron Multipliers, Glass Extrusion & Fabrication and Motion Control Products. With a state of the art fabrication and production facility, our dedicated team has been delivering excellence in manufacturing and customer satisfaction over the last 20 years.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Elite One Source Nutritional Services, Inc together with its subsidiary provides contract manufacturing services for nutritional and dietary supplements. The company was incorporated in 2013 and is based in Missoula, Montana. As of February 7, 2018, Elite One Source Nutritional Services, Inc operates as a subsidiary of DCC Health & Beauty Solutions Limited.

Nexcelom Bioscience

Private Placement in 2018
Nexcelom Bioscience LLC, a biotechnology company, develops and markets image cytometry products for cell analysis in life science and biomedical research. It offers Cellometer, helps to count and analyze cell lines and primary cells, through bright field and fluorescence imaging modes; and Celigo, which provides high image quality, high throughput image cytometry system for adherent and suspension cells in microwell plates. Additionally, the company also offers fluorescent reagents and kits for cell counting and cell-based assays. The company provides its products for life science industry. The company was incorporated in 2003 and is based in Lawrence, Massachusetts.

Corpus Medical

Venture Round in 2017
CORPUS MEDICAL INC. provides top-notch consulting services for the medical device industry. We have extensive experience in developing a wide array of medical devices, we work fast and smart and we are passionate about what we do. From concept to market, let us be your partner.

Canopy Biosciences

Venture Round in 2019
Canopy Biosciences is biotechnological company that provides products and services for gene editing and personalized medicine. The gene editing technology is called TUNR and targets translation elongation by inserting polyA tracks into targeted coding regions of the genome. This change then decreases the levels of mRNA transcribed from the gene and therefore suppresses protein expression. It was initially developed by Professor Sergej Djuranovic at Washington University School of Medicine and Professor Rachel Green from Johns Hopkins University. Canopy Biosciences was formed in 2016 and is headquartered in Saint Louis, Missouri.

Cyclis Pharmaceuticals

Series A in 2002
Cyclis is researching and developing small-molecule cancer drugs based on a novel technology designed to selectively kill cancer cells and preserve normal cells by restoring and activating cellular checkpoints known to be defective in cancers.

MedPharm

Venture Round in 2018
MedPharm is a world-leading contract provider of topical and transdermal product design and development services. Our delivery of robust and innovative research has commanded recognition from regulators and investors alike. We utilise our unique cost-effective performance testing models to mitigate risk and accelerate development times.

Nitinol Devices & Components

Venture Round in 2011
NDC is a privately held medical device company headquartered in Fremont, CA, USA. Focused on the medical field, NDC provides manufacturing, research, development, regulatory and technical support on all aspects of Nitinol technology and processing, and is aggressively expanding its capabilities to meet the growing demand for its shape-memory and superelastic Nitinol products.

Genoptix

Merger/Acquisition in 2017
As a pioneering force in oncology, Genoptix regularly participates in industry conferences to share their findings, discuss emerging solutions, and create meaningful connections to advance the community.

Canopy Biosciences

Seed Round in 2017
Canopy Biosciences is biotechnological company that provides products and services for gene editing and personalized medicine. The gene editing technology is called TUNR and targets translation elongation by inserting polyA tracks into targeted coding regions of the genome. This change then decreases the levels of mRNA transcribed from the gene and therefore suppresses protein expression. It was initially developed by Professor Sergej Djuranovic at Washington University School of Medicine and Professor Rachel Green from Johns Hopkins University. Canopy Biosciences was formed in 2016 and is headquartered in Saint Louis, Missouri.

Endeca

Series B in 2001
Endeca provides enterprise search for large companies including Borders, Boeing, the Census Bureau, the EPA, Ford, Hallmark, IBM, and Toshiba. The company specializes in guided search, auto-categorizing results based on the keywords someone enters. Endeca charges from $100,000 to more than $10 million per installation. Endeca competes with FAST Search & Transfer, which was [acquired](http://www.techcrunch.com/2008/01/08/microsoft-has-announced-a-takeover-bid-for-fast-search-transfer-priced-at-12-billion/) by Microsoft for 1.2 Billion in January 2008.

GeneWerk

Private Placement in 2020
GeneWerk GmbH was founded in July 2014 by Prof. Dr. Christof von Kalle, Dr. Manfred Schmidt and Dr. Annette Deichmann with participation of the German Cancer Research Center (DKFZ) Heidelberg. their team has long lasting experience in the area of integration site analysis, high throughput sequencing, whole genome sequencing and bioinformatics. It is very innovative in developing new analysis methods – perhaps also for your project?

New England Peptide

Private Placement in 2019
New England Peptide prides itself on providing top-notch peptides and excellent customer service. We strive to constantly better ourselves and, in the process, the industry.

Cequent Pharmaceuticals

Series A in 2007
An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases – from inflammatory diseases to cancer – based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006. In July 2010, Cequent Pharmaceuticals was acquired by Marina Biotech, Inc (formerly MDRNA, Inc) for $46M.

Signature Genomic Laboratories

Venture Round in 2008
A Spokane, Wash.-based provider of molecular cytogenetic diagnostic services.

AnaBios

Private Equity Round in 2022
AnaBios specializes in enabling human-focused drug discovery. As a CRO, AnaBios provides products and services for every stage of drug discovery. Through proprietary technology based on the use of human donor organs and tissues, it studies ex vivo human responses to drugs and further investigate the molecular and functional basis of relevant human physiology. Its research focuses primarily on the areas of high, unmet medical need, including cardiac disease and safety, pain, PKD kidney disease, and neurodegeneration. In partnership with Fortune 500 pharmaceutical companies, contract research organizations, and universities, the company's mission is to develop therapeutic advancements to help patients live longer, healthier, and more productive lives.

Bioventus

Venture Round in 2012
Bioventus LLC develops and/or markets orthobiologic solutions for bone fusion and osteoarthritis. Its active healing therapies product line supports accelerated and more complete healing of bone fractures, and treats the chronic pain associated with osteoarthritis; and bone healing solutions work to enhance the body’s natural healing process. The company also provides injection therapies that treat osteoarthritic joints relieve pain and help bring mobility back to the patient; and surgical orthobiologics. Its products are available through a network of distributors. The company was incorporated in 2011 and is based in Durham, North Carolina. Bioventus LLC operates as a subsidiary of Bioventus Inc.

ESA Bioscience

Acquisition in 2004
ESA Bioscience is a company that was acquired by Ampersand Capital Partners in 2004.

Avista Pharma

Seed Round in 2016
Avista Pharma Solutions is a contract testing, development and manufacturing organization encompassing over 200,000 square feet of laboratory and manufacturing space across three locations (Agawam, MA, Durham, NC, and Longmont, CO), providing pharmaceutical, animal health and medical device clients with a broad suite of scientifically-differentiated services ranging from early drug development to drug product manufacturing.

Genezen Laboratories

Acquisition in 2021
Genezen Laboratories is focused on supporting the demands of the current and future gene and cell therapy manufacturing market-making viral vector production accessible to both early-stage, growth-oriented companies, and well-established industry leaders. The Genezen mission of gene and cell therapy acceleration is the outcome of expansive knowledge and experience in the industry and working with the nation’s leading institutions. Our developed solutions provide the right expertise, capacity, and technology to bring breakthrough treatments to market.

Syft Technologies

Private Equity Round in 2022
Syft Technologies Ltd. develops, markets, and supports air analysis solutions for research teams, commercial laboratories, government agencies, and private companies. The company offers Voice200 SIFT-MS instruments that allow users to identify and measure a range of compounds simultaneously; Sample Collection Case that combines sample collection hardware into one compact and portable package; and Sample Bag Flushing Station that simultaneously cleans sample bags. Its analytical solutions are used in container air analysis; food, flavor, and fragrance; medical research; environmental; and oil and gas exploration market sectors. The company offers its products through a network of distributors in Benelux, Germany, Austria, Switzerland, Italy, and France. Syft Technologies Ltd. was founded in 2002 and is based in Christchurch, New Zealand. The company has locations in Christchurch, New Zealand; Warrington, the United Kingdom; and Pittsburgh, Pennsylvania.

Magritek Ltd

Private Equity Round in 2021
Magritek is a service provider of complete NMR and MRI solutions.

Bioventus

Seed Round in 2012
Bioventus LLC develops and/or markets orthobiologic solutions for bone fusion and osteoarthritis. Its active healing therapies product line supports accelerated and more complete healing of bone fractures, and treats the chronic pain associated with osteoarthritis; and bone healing solutions work to enhance the body’s natural healing process. The company also provides injection therapies that treat osteoarthritic joints relieve pain and help bring mobility back to the patient; and surgical orthobiologics. Its products are available through a network of distributors. The company was incorporated in 2011 and is based in Durham, North Carolina. Bioventus LLC operates as a subsidiary of Bioventus Inc.

Adaptas Solutions

Private Equity Round in 2018
Adaptas Solutions is a strategic OEM supplier for key products and manufacturing service for analytical and laboratory equipment manufacturers.

Ortho Organizers

Seed Round in 2006
Ortho Organizers, a full-line manufacturer and distributor of orthodontics products.

RadPharm

Series B in 2007
RadPharm provides radiopharmaceutical products to medical practices in Australia. Its product portfolio includes sterile vials, cold kits, contract manufacturing, and more.

Brammer Bio

Seed Round in 2016
Brammer Bio, LLC develops and manufactures cell and gene therapies for pharmaceutical and biotechnology industries. It offers pre-clinical process and analytical development, process optimization, process scale-up, process and analytical qualification, and clinical and commercial supply of drug substances and formulated drug products. The company was formerly known as Brammer Biopharmaceuticals, LLC and changed its name in Brammer Bio, LLC in April 2016. Brammer Bio, LLC was incorporated in 2013 and is based in Cambridge, Massachusetts. As of April 30, 2019, Brammer Bio, LLC operates as a subsidiary of Thermo Fisher Scientific Inc.

Vibalogics

Acquisition in 2019
Vibalogics is a contract development and manufacturing organization focused on complex live biological products. Vibalogics offers process development, manufacturing and fill & finish of products for biopharmaceutical companies involved in the development of oncolytic viral therapies, gene therapies, and vaccines.

Bako Diagnostics

Seed Round in 2009
Bako Integrated Physician Solutions is the premier provider of diagnostic and therapeutic services focusing on the skin, soft tissue and bone of the lower extremity. Their pathology team provides not just information, but also intelligence to enable better patient care.

Prolepha Packaging B.V.

Private Placement in 2020
Prolepha Packaging B.V. provides pharmaceutical contract packaging services. The company is based in Etten-Leur, the Netherlands. As of November 9, 2011, Prolepha Packaging B.V. operates as a subsidiary of Tjoapack B.V.

Viadux

Venture Round in 2002
Viadux is a leading provider of in-building broadband access solutions for the telecommunications and cable industries. The company partners with service providers to deliver high-speed data, video and voice services to small-to-medium enterprises (SMEs) and residential customers in the Multi-Tenant Unit (MTU/MDU) market.

LightPointe

Series A in 2000
LightPointe Communications, Inc. (a.k.a. LightPointe Wireless) is privately held. The company was launched in 1998 and is headquartered in San Diego, CA, with regional offices/presence in Europe (Germany & France) and Asia (Thailand). LightPointe also provides solutions via its AirePointe Security & Government Solutions Division (www.AirePointe.com). LightPointe is the number one manufacturer in the world of point-to-point Gigabit Ethernet Free Space Optics and Hybrid Optical-Radio Bridges, and manufactures a complete line of 4G/LTE backhaul radios (60 GHz & 70/80 GHz e-band) for telecom carriers and enterprises such as businesses, schools, the military & government agencies. With over $80 million in product development and over eight key patents, LightPointe has deployed thousands of Gigabit Ethernet bridges and digital video/security backhaul solutions worldwide.

GENEWIZ

Venture Round in 2015
GENEWIZ is a leading global genomics service company. A full-service provider, GENEWIZ provides DNA sequencing, gene synthesis, molecular biology, next generation sequencing, bioinformatics, and GLP regulatory services. From the company’s founding, GENEWIZ has maintained its unwavering commitment to providing customers with the best value. Excelling in both science and customer support, GENEWIZ is dedicated to accelerating scientific discovery, as well as to developing and delivering innovative solutions for translational medicine and healthcare. Easily accessible around the world, GENEWIZ is the preferred partner at leading academic, pharmaceutical, biotechnology, agricultural, government, and clinical institutions. At GENEWIZ, it is their mission to contribute to the advancement of life sciences and technologies. Together with their clients, they can make a difference in the pursuit of scientific discoveries, better healthcare, a greener environment, and abundant food supplies. Their goal is to be the best in the world and the best for the world. Headquartered in South Plainfield, NJ, GENEWIZ is a privately-held global enterprise with locations in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; Langen, Germany; and Tokyo, Japan.

Endeca

Series C in 2002
Endeca provides enterprise search for large companies including Borders, Boeing, the Census Bureau, the EPA, Ford, Hallmark, IBM, and Toshiba. The company specializes in guided search, auto-categorizing results based on the keywords someone enters. Endeca charges from $100,000 to more than $10 million per installation. Endeca competes with FAST Search & Transfer, which was [acquired](http://www.techcrunch.com/2008/01/08/microsoft-has-announced-a-takeover-bid-for-fast-search-transfer-priced-at-12-billion/) by Microsoft for 1.2 Billion in January 2008.

Genome Diagnostics

Private Equity Round in 2019
GenDx develops and markets a comprehensive line of In Vitro Diagnostic (IVD) tests and services, analysis software and education. The company is a pioneer in the area of Sequencing-Based Typing (SBT) for transplantation offering high resolution HLA typing methods for Sanger and NGS techniques.

MedPharm

Private Placement in 2018
MedPharm is a world-leading contract provider of topical and transdermal product design and development services. Our delivery of robust and innovative research has commanded recognition from regulators and investors alike. We utilise our unique cost-effective performance testing models to mitigate risk and accelerate development times.

FirstRain

Venture Round in 2006
FirstRain, Inc. develops a business analytics platform that assists Fortune 1000 companies in building their strategies, creating lead generation campaigns, discovering and developing new sales opportunities, and identifying business risks. The company was founded in 2000 and is headquartered in San Mateo, California. As of July 31, 2017, FirstRain, Inc. operates as a subsidiary of Ignite Technologies, Inc.

LightPointe

Series B in 2001
LightPointe Communications, Inc. (a.k.a. LightPointe Wireless) is privately held. The company was launched in 1998 and is headquartered in San Diego, CA, with regional offices/presence in Europe (Germany & France) and Asia (Thailand). LightPointe also provides solutions via its AirePointe Security & Government Solutions Division (www.AirePointe.com). LightPointe is the number one manufacturer in the world of point-to-point Gigabit Ethernet Free Space Optics and Hybrid Optical-Radio Bridges, and manufactures a complete line of 4G/LTE backhaul radios (60 GHz & 70/80 GHz e-band) for telecom carriers and enterprises such as businesses, schools, the military & government agencies. With over $80 million in product development and over eight key patents, LightPointe has deployed thousands of Gigabit Ethernet bridges and digital video/security backhaul solutions worldwide.

Chantest

Venture Round in 2007
ChanTest has developed the world's most complete library of validated human ion channel-expressing cell lines to serve all the ion channel needs of its pharmaceutical and biotech customers. Services range from early functional screens for profiling drug candidates or ranking within profiles during the drug-discovery process – to a complete set of in vitro GLP service products for cardiac risk assessment. ChanTest works in partnership with customers to speed the drug-development process, save time and money, and ultimately – to help make better, safer drugs.

Vernal Biosciences

Series A in 2023
Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.